Report overview
Due to the COVID-19 pandemic, the global Endocrine System Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Endocrine System Drugs market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Endocrine System Drugs landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Diabetes Drug accounting for % of the Endocrine System Drugs global market in 2022, is projected to value US$ million by 2030, growing at a revised % CAGR from 2023 to 2030. While Hospitals segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2030.
The global major manufacturers of Endocrine System Drugs include Novo Nordisk, Sanofi, Merck, Eli Lilly, AstraZeneca and AbbVie, etc. In terms of revenue, the global 3 largest players have a % market share of Endocrine System Drugs in 2022.
This report focuses on Endocrine System Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Endocrine System Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Endocrine System Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Diabetes Drug
Human Growth Hormones
Thyroid Hormone Disorder Drugs
Others
Segment by Application
Hospitals
Clinics
Medical Center
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novo Nordisk
Sanofi
Merck
Eli Lilly
AstraZeneca
AbbVie
